EC Number   |
Disease |
PubMed ID |
Title of Publication |
Category |
Confidence Level |
|---|
   3.1.4.53 | Vascular System Injuries |
24925970 |
Phosphodiesterase type 4 blockade prevents platelet-mediated neutrophil recruitment at the site of vascular injury. |
therapeutic application
unassigned |
1
0 |
| 3.1.4.53 | Vascular System Injuries |
25640159 |
PDE4 inhibition reduces neointima formation and inhibits VCAM-1 expression and histone methylation in an Epac-dependent manner. |
ongoing research
therapeutic application
unassigned |
1
1
0 |
| 3.1.4.53 | Vasculitis |
16246509 |
Mesenteritis precedes vasculitis in the rat mesentery after subacute administration of a phosphodiesterase type 4 inhibitor. |
causal interaction
therapeutic application
unassigned |
4
4
0 |
| 3.1.4.53 | Ventricular Dysfunction, Left |
7669959 |
Hemodynamic effects of the novel selective cAMP-phosphodiesterase III inhibitor R 80122 in anesthetized patients with moderate left ventricular dysfunction before coronary artery bypass grafting. |
causal interaction
therapeutic application
unassigned |
2
4
0 |
| 3.1.4.53 | Virus Diseases |
212566 |
Nucleases and adenosine 3',5'-cyclic monophosphate phosphodiesterase activities in murine sarcoma virus (Moloney)-infected mice. |
causal interaction
ongoing research
unassigned |
1
3
0 |
| 3.1.4.53 | Vitiligo |
32709274 |
Vitiligo: Targeted Therapies Add Color to Disease Pathophysiology. |
therapeutic application
unassigned |
4
0 |
